Pulse Biosciences, Inc. reported its financial results for the first quarter of 2026, revealing a product revenue of $401,000, marking the company's first revenue generation compared to no revenue in the same period last year. The company incurred a net loss of $18.6 million, an increase from the $16.8 million loss reported in the first quarter of 2025. The increase in losses was attributed to higher research and development expenses, which rose by $2.3 million to $12.6 million, driven by increased costs associated with clinical trials and external research services.
Total expenses for the quarter were $19.6 million, up from $18.0 million in the prior year. The cost of product revenue was $370,000, reflecting the initial costs associated with the limited market release of the Vybrance Percutaneous Electrode System. Selling, general, and administrative expenses decreased to $6.6 million from $7.7 million, primarily due to a reduction in stock-based compensation expenses following executive departures.
In terms of operational developments, Pulse Biosciences announced a strategic realignment in March 2026 to focus on the development of its nsPFA electrophysiology catheters and other cardiac devices for treating atrial fibrillation (AF). This decision follows positive clinical data from a feasibility study of the nPulse Cardiac Catheter System. The company is also pursuing the commercialization of its Vybrance System, which received FDA clearance for soft tissue ablation procedures. As of March 31, 2026, the company had cash and cash equivalents of $68.3 million, down from $80.7 million at the end of 2025.
The company’s employee headcount remained stable, with no significant changes reported. However, the filing indicated that the company may need to raise additional capital to support ongoing operations and product development. On May 11, 2026, Pulse Biosciences sold 675,233 shares of common stock for net proceeds of approximately $12.9 million, which the company believes will be sufficient to fund its operations for at least the next twelve months. The outlook remains cautious, with the company acknowledging the potential need for further financing to sustain its business strategy and development initiatives.
About Pulse Biosciences, Inc.
Pulse Biosciences develops nonthermal ablation devices utilizing patented Nano-pulse Stimulation (NPS) technology for medical applications in dermatology, cardiology, and soft tissue treatment. Its core product, the CellFX System, and related platforms aim to improve outcomes by precisely targeting cells while sparing surrounding tissue. The company focuses on innovative, minimally invasive therapies for conditions like benign skin lesions and atrial fibrillation, emphasizing safety, efficacy, and regulatory approval.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.